Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome
Open accessThe DOI matches its Crossref record; 71 of the 71 references it cites were found in a registry or an index; none of the 98 sources its claims cite is checked for support yet.
Abstract
To understand and treat immunology-related diseases, a comprehensive, unbiased characterization of major histocompatibility complex (MHC) peptide ligands is of key importance. Preceding the analysis by mass spectrometry, MHC class I peptide ligands are typically isolated by MHC immunoaffinity chromatography (MHC-IAC) and less often by mild acid elution (MAE). MAE may provide a cheap alternative to MHC-IAC for suspension cells but has been hampered by the high number of contaminating, MHC-unrelated peptides. Here, we optimized MAE, yielding MHC peptide ligand purities of more than 80%. When compared with MHC-IAC, obtained peptides were similar in numbers, identities, and to a large extent intensities, while the percentage of cysteinylated peptides was 5 times higher in MAE. The latter benefitted the discovery of MHC-allotype-specific, distinct cysteinylation frequencies at individual positions of MHC peptide ligands. MAE revealed many MHC ligands with unmodified, N-terminal cysteine residues which get lost in MHC-IAC workflows. The results support the idea that MAE might be particularly valuable for the high-confidence analysis of post-translational modifications by avoiding the exposure of the investigated peptides to enzymes and reactive molecules in the cell lysate. Our improved and carefully documented MAE workflow represents a high-quality, cost-effective alternative to MHC-IAC for suspension cells.
Overview
CoChat Summary
TL;DR
Optimized mild acid elution (MAE) yields HLA class I peptide purities above 80% and peptide numbers, identities, and MS1 intensities largely comparable to MHC immunoaffinity chromatography (MHC-IAC). MAE recovers about 5-fold more cysteinylated peptides and better preserves N-terminal unmodified cysteine residues, making it a cost-effective alternative for suspension cells, though it remains unsuitable for solid tissue or frozen cells.
Key findings
- Optimized MAE achieved >80% MHC peptide ligand purity; >82% of identified 8–12-mers were assigned to an appropriate MHC allotype using NetMHC IC50 <500 nM. MAE yielded 9% (JY) to 30% (THP-1) fewer peptides than MHC-IAC. Of 2072 total JY peptides, 50% were found by both methods; of 1268 THP-1 peptides, 36% were shared. Strong binders overlapped 55% (JY) and 41% (THP-1), while putative contaminants overlapped only 17% (JY, 32/189) and 7% (THP-1, 12/168).
- Quantitative MS1 data correlated between MAE and MHC-IAC with R² = 0.65 (JY) and R² = 0.62 (THP-1); 69.3% and 63.2% of shared peptides differed by less than 2-fold in mean MS1 intensity. The overall median MS1 intensity of identified MHC ligands differed by less than 2% between extraction methods.
- MAE showed on average >5-fold higher relative cysteinylated peptides than MHC-IAC: mean 2.91% vs 0.53% (P = 2.6 × 10⁻⁶). Cysteinylation was enriched among HLA-A*02:01 binders and diminished among HLA-B*07:02 binders; preferred at position C-1 for both allotypes, and at C-4 for HLA-A*02:01 but not HLA-B*07:02. MAE also revealed carbamidomethylated N-terminal cysteine residues.
- In MHC-IAC, acetonitrile-based ultrafilter rinsing yielded 2–3 times more peptide identifications and boosted MS1 intensities 27-fold and 41-fold versus the first ultrafiltrate, especially for hydrophobic peptides. Repeated MAE recovered only 2.1% and 3.5% of peptides relative to the first MAE, indicating acidic elution was nearly complete; <2% of cells survived the repeated MAE.
Methods
- Direct comparison of optimized MAE and MHC-IAC starting from the same cell cultures, primarily JY and THP-1 suspension cells (LCL5 also described in Methods). MAE used 5 × 10⁸ JY cells and 1.25 × 10⁸–1.5 × 10⁹ THP-1 cells; MHC-IAC used W6/32 for HLA-A, -B, -C and L243/Tü39 for MHC-II.
- Peptides were analyzed by LC-MS/MS on an LTQ Orbitrap XL and an Orbitrap Fusion. Data were processed with Proteome Discoverer, Mascot/Sequest, and Percolator with a peptide spectral match FDR ≤5%; searches allowed 8–12-mers and variable modifications including oxidation, cysteinylation, and carbamidomethylation.
- Analyses included peptide overlap, MS1 intensity correlation, MHC allotype assignment via NetMHC/Syfpeithi, positional cysteinylation frequencies, repeated MAE, organic-solvent elution tests, and acetonitrile ultrafilter rinsing. Structural exposure measures used selected HLA-A*02:01 and HLA-B*07:02 PDB crystal structures.
Limitations
- Stated: MAE is not applicable to solid tissue, appears unsuitable for frozen cells, and cannot sample MHC-II; MHC-IAC remains necessary for solid tissues and frozen cells. Repeated MAE is not beneficial because it causes substantial cellular stress, with <2% cell survival.
- Stated: the relative contribution of W6/32 antibody bias versus sample-processing bias could not be deduced from this study, and additional studies are needed. The structural explanation for cysteinylation patterns remains a hypothesis requiring crystal structures with cysteinylated MHC peptide ligands. HLA-B*07:02 structural analysis was limited by only four PDB entries, two of which were putatively not representative.
- Evident from the text: the main comparison focused on two suspension cell lines and a limited set of HLA allotypes; MHC-IAC was deliberately performed without cysteine protection for representativeness, which may affect cysteine-related comparisons. MAE by design samples only cell-surface MHC-I and excludes intracellular MHC compartments.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
0 Valid · 2 Not valid · 61 Not checked · 171 Own results and interpretations
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“As expected, MHC-IAC yielded an even higher fraction of peptides of the appropriate length (99% for JY and 98% for THP-1, Supplementary Figure S6).”
§ Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome > Results > Peptides Extracted by MAE and MHC-IAC Share Generic Features
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Specifically, MAE yielded 9% (JY cells) to 30% (THP-1 cells) fewer peptides than MHC-IAC but also revealed MHC peptide ligands not detected by MHC-IAC.”
§ Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome > Results > Peptides Extracted by MAE and MHC-IAC Largely Overlap
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“but even LC-MS triplicates of one and the same sample provided only 64% overlap due to the stochastic nature of the applied data dependent acquisition (DDA) MS scheme (Supplementary Figure S3E).”
§ Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome > Results > Peptides Extracted by MAE and MHC-IAC Largely Overlap
plainstates a causeSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“In MAE, the summed fraction of 8- to 12-mers among all identified peptides was 96% (JY) and 90% (THP-1), respectively”
§ Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome > Results > Peptides Extracted by MAE and MHC-IAC Share Generic Features
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Comparing MAE versus MAE or MHC-IAC versus MHC-IAC from a single cell culture harvesting (like in the comparison of MAE and MHC-IAC), the overlap was higher”
§ Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome > Results > Peptides Extracted by MAE and MHC-IAC Largely Overlap
plainstates an associationSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
153 more claims
Create a free account to see all 234 claims and to verify the 96 references still open.
- It may state two separate claims as one. 45
- The quote only partly states this claim. 2
- Probably not a substantial claim. 34
Citations
Cites
Eng, J. K., McCormack, A. L., & Yates, J. R. (1994) · Journal of the American Society for Mass Spectrometry · doi:10.1016/1044-0305(94)80016-2 · Cited by 6,484
2016 update of the PRIDE database and its related tools
Vizcaíno, J. A., Csordas, A., del-Toro, N., Dianes, J. A., Griss, J., Lavidas, I., Mayer, G., Perez-Riverol, Y., Reisinger, F., Ternent, T., et al. (2016) · Nucleic Acids Research · doi:10.1093/nar/gkv1145 · Cited by 3,451
Semi-supervised learning for peptide identification from shotgun proteomics datasets
Käll, L., Canterbury, J. D., Weston, J., Noble, W. S., & MacCoss, M. J. (2007) · Nature Methods · doi:10.1038/nmeth1113 · Cited by 2,424
Allele-specific motifs revealed by sequencing of self-peptides eluted from MHC molecules
Falk, K., Rötzschke, O., Stevanovié, S., Jung, G., & Rammensee, H.-G. (1991) · Nature · doi:10.1038/351290a0 · Cited by 2,411
Self-citationSYFPEITHI: database for MHC ligands and peptide motifs
Rammensee, H. G., Bachmann, J., Emmerich, N. P. N., Bachor, O. A., & Stevanović, S. (1999) · Immunogenetics · doi:10.1007/s002510050595 · Cited by 2,314
Self-citationEstablishment and characterization of a human acute monocytic leukemia cell line (THP‐1)
Tsuchiya, S., Yamabe, M., Yamaguchi, Y., Kobayashi, Y., Konno, T., & Tada, K. (1980) · International Journal of Cancer · doi:10.1002/ijc.2910260208 · Cited by 2,254
Towards a systems understanding of MHC class I and MHC class II antigen presentation
Neefjes, J., Jongsma, M. L. M., Paul, P., & Bakke, O. (2011) · Nature Reviews Immunology · doi:10.1038/nri3084 · Cited by 2,044 · cited 1×
“6 The sum of all MHC peptide ligands from a given biological entity is referred to as the MHC peptide ligandome or the MHC immunopepti-dome.”
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens
Gubin, M. M., Zhang, X., Schuster, H., Caron, E., Ward, J. P., Noguchi, T., Ivanova, Y., Hundal, J., Arthur, C. D., Krebber, W.-J., et al. (2014) · Nature · doi:10.1038/nature13988 · Cited by 1,974
Self-citationBarnstable, C. (1978) · Cell · doi:10.1016/0092-8674(78)90296-9 · Cited by 1,916
Olsen, J. V., de Godoy, L. M. F., Li, G., Macek, B., Mortensen, P., Pesch, R., Makarov, A., Lange, O., Horning, S., & Mann, M. (2005) · Molecular & Cellular Proteomics · doi:10.1074/mcp.t500030-mcp200 · Cited by 1,510
Cited by
AlphaPeptDeep: a modular deep learning framework to predict peptide properties for proteomics
Zeng, W.-F., Zhou, X.-X., Willems, S., Ammar, C., Wahle, M., Bludau, I., Voytik, E., Strauss, M. T., & Mann, M. (2022) · Nature Communications · doi:10.1038/s41467-022-34904-3 · Cited by 213
Peptide-based vaccine for cancer therapies
Buonaguro, L., & Tagliamonte, M. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1210044 · Cited by 110
Proteomic discovery of chemical probes that perturb protein complexes in human cells
Lazear, M. R., Remsberg, J. R., Jaeger, M. G., Rothamel, K. L., Her, H.-L., DeMeester, K. E., Njomen, E., Hogg, S. J., Rahman, J. A., Whitby, L. R., et al. (2023) · Molecular Cell · doi:10.1016/j.molcel.2023.03.026 · Cited by 93
Klaeger, S., Apffel, A. M., Clauser, K. R., Sarkizova, S., Oliveira, G., Rachimi, S., Le, P. M., Tarren, A. Y., Chea, V. A., Abelin, J. G., et al. (2021) · Molecular & Cellular Proteomics · doi:10.1016/j.mcpro.2021.100133 · Cited by 54
Nelde, A., Schuster, H., Heitmann, J. S., Bauer, J., Maringer, Y., Zwick, M., Volkmer, J.-P., Chen, J. Y., Stanger, A. M. P., Lehmann, A., et al. (2023) · Blood Cancer Discovery · doi:10.1158/2643-3230.bcd-23-0020 · Cited by 35
Self-citation
Metadata
- Authors
- Sturm, T., Sautter, B., Wörner, T. P., Stevanović, S., Rammensee, H.-G., Planz, O., Heck, A. J. R., & Aebersold, R.
- Affiliations
- Utrecht University (NL)
- University of Tübingen (DE)
- Utrecht University , , ,
- University of Tübingen , , ,
- University of Zurich (CH)
- Corresponding author
- Sturm, Theo
- Aebersold, Ruedi
- Venue
- Journal of Proteome Research
- Publisher
- American Chemical Society (ACS)
- Published
- 2020-11-03
- Volume
- 20
- Issue
- 1
- Pages
- 289-304
- ISSN
- 1535-3893 (ISSN-L)
- 1535-3907
- PMC
- PMC7786382
- OpenAlex
- W3097954807
- Cited by
- 63
- References
- 71
- Citations by year
- 2026: 12 · 2025: 6 · 2024: 14 · 2023: 12 · 2022: 12 · 2021: 7
- FWCI
- 1.98
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Journal of Proteome Research (publishedVersion, cc-by-nc-nd)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Repository for Publications and Research Data (ETH Zurich) (publishedVersion, cc-by-nc-nd)
- Utrecht University Repository (Utrecht University) (submittedVersion, other-oa)
- ETH Zürich Research Collection (cc-by-nc-nd)
- Funders
- Horizon 2020 Framework Programme (2-73838-14)
- H2020 European Research Council (670821, ERC-2008-AdG_20080422)
- H2020 Future and Emerging Technologies (686547)
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung (3100A0-688 107679)
- Nederlandse Organisatie voor Wetenschappelijk Onderzoek (SPI.2017.028)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › vaccines and immunoinformatics approaches
- Physical Sciences › Chemistry › Spectroscopy › Advanced Proteomics Techniques and Applications
- Physical Sciences › Chemistry › Organic Chemistry › Chemical Synthesis and Analysis
- Keywords
- immunopeptidome, cysteine modification, post-translational modification, peptide purification, suspension-cultured cells
- MeSH terms
- Chromatography, Affinity, Cysteine, Peptides, Protein Binding, Mass Spectrometry, Histocompatibility Antigens Class I
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-21, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-21 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome. https://app.cochat.ai/papers/10.1021/acs.jproteome.0c00386
- The paper
- Sturm, T., Sautter, B., Wörner, T. P., Stevanović, S., Rammensee, H.-G., Planz, O., Heck, A. J. R., & Aebersold, R. (2021). Mild Acid Elution and MHC Immunoaffinity Chromatography Reveal Similar Albeit Not Identical Profiles of the HLA Class I Immunopeptidome. Journal of Proteome Research. https://doi.org/10.1021/acs.jproteome.0c00386
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.